21. Potential Population Impact

If lepodisiran receives approval, it could benefit millions worldwide who currently lack treatment options for genetic cholesterol. By cutting heart attack and stroke risk, its impact could extend to over 1 billion people with elevated Lp(a). This marks a major advance in global cardiovascular health.
Find more information at AHA Journals.